Related Experiment Video

Updated: Jul 17, 2026

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
06:47

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

Published on: December 5, 2020

Absence of an active metabolite for the triazole antifungal pramiconazole

Jannie Ausma1, Gennethel Pennick, Hilde Bohets

  • 1Barrier Therapeutics NV, Cipalstraat 3, Geel, Belgium. jausma@barriertherapeutics.be

Acta Dermato-Venereologica
|January 17, 2007
PubMed

Insights

Pramiconazole, an antifungal, was studied for active metabolites. Research found no active metabolites in human serum after oral dosing, indicating the parent drug is likely responsible for its antifungal effects.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Metabolism

Background:

  • Pramiconazole is a promising antifungal agent for skin infections caused by dermatophytes and yeasts.
  • The precise mechanism of action, whether via the parent compound or active metabolites, remains unclear.

Purpose of the Study:

  • To investigate the in vitro metabolism and metabolic stability of pramiconazole.
  • To determine if pramiconazole is converted into active metabolites in humans following oral administration.

Main Methods:

  • In vitro studies utilized subcellular liver fractions and isolated hepatocytes from various species.
  • Human serum samples from healthy volunteers receiving oral pramiconazole were analyzed using agar diffusion bioassay and liquid chromatography-tandem mass spectrometry.

Main Results:

  • Pramiconazole exhibited slow metabolism in vitro, characterized by slow enzyme-mediated disappearance.
  • Analysis of human serum samples revealed no detectable active metabolites after a one-week oral dosage regimen.

Conclusions:

  • The metabolism of pramiconazole is generally slow across different species.
  • Oral administration of pramiconazole in humans does not appear to generate active metabolites in the serum.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Assessing Cytotoxicity of Metabolites of Typical Triazole Pesticides in Plants08:22

Assessing Cytotoxicity of Metabolites of Typical Triazole Pesticides in Plants

Published on: December 22, 2023

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...